Blog

Our Story

Q&A with Naike Ledan, Associate Director of International Policy & Advocacy 

Access to Medicines

Switzerland and Mexico’s Communication to the TRIPS Council is Replete with Disinformation and Their Que... 

Access to Medicines

Bad Faith from Big Pharma, Rich Countries and the WTO Poison WTO TRIPS Waiver Negotiations 

Access to Medicines

Time to Walk Away from the WTO Proposed Text 

Access to Medicines

The Quad TRIPS Waiver Text is not a Compromise; It is an Abomination 

Access to Medicines

Moderna’s Global Public Health Strategy:  Parsing the Hype and Shameful Access Gaps 

Health Justice

Africa’s Key Populations Demand Bold Action, Not Empty Promises 

Access to Medicines

Merck’s Molnupiravir – Overcoming impending barriers to affordable global access 

Access to Medicines

Biggest Roadblock to Biden-Convened COVID-19 Summit’s Success: Fealty to Moderna and Pfizer 

COVID-19

The Global Fund: A Foundation for Health Equity 

Access to Medicines

Biden’s $2.7 billion investment in supply chains is a cynical boost to Big Pharma’s continued control over... 

Health Justice

Our Shared Struggles for Health Justice 

Access to Medicines

The European Union, Led by Germany’s Chancellor Merkel, Chokes Off Progress on Intellectual Property Waiver ... 

Access to Medicines

Disinformation, Diversion, and Delay: The Real Text of the European Union’s Communication to the WTO TRIPS C... 

Access to Medicines

The Impracticality of Relying on Compulsory Licenses to Expand Production Capacity for COVID-19 Vaccines 

SEE MORE